3-butyl-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one | 792122-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-butyl-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one
• 英文别名: 3-Butyl-1-(4-methylphenyl)-3,4-dihydroquinolin-2(1H)-one；3-butyl-1-(4-methylphenyl)-3,4-dihydroquinolin-2-one
• CAS: 792122-74-8
• 化学式: C₂₀H₂₃NO
• 分子量: 293.409
• InChiKey: UXUFFBIOYSBXKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-butyl-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one 、 3-ethyl-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one 、 3-ethyl-3-(3-methylamino-propyl)-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one 反应 0.2h， 以to give 334 mg of the racemate的产率得到3-butyl-3-(3-methylamino-propyl)-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Quinolone derivatives

  摘要：

  本发明涉及式（I）化合物，其中—X—，n，R1，R3和Ar—具有在此定义的值，它们的制备以及用作药物的用途。

  公开号：

  US20070105845A1
• 作为产物：
  描述：

  1-(4-甲基苯基)-3,4-二氢喹啉-2-酮 、 1-碘丁烷 、 生成 3-butyl-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Quinolone derivatives

  摘要：

  本发明涉及式（I）化合物，其中—X—，n，R1，R3和Ar—具有在此定义的值，它们的制备以及用作药物的用途。

  公开号：

  US20070105845A1

文献信息

• 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1622874B1

  公开（公告）日：2007-10-03
• Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
  申请人：Allen John Albert

  公开号：US20060241188A1

  公开（公告）日：2006-10-26

  Provided are methods and medicaments for treating a Pervasive Developmental Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.
• Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
  申请人：Allen John Albert

  公开号：US20070015786A1

  公开（公告）日：2007-01-18

  Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.
• Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
  申请人：Kelsey Kenneth Douglas

  公开号：US20070032554A1

  公开（公告）日：2007-02-08

  Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.
• Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
  申请人：Sumner Russell Calvin

  公开号：US20070105960A1

  公开（公告）日：2007-05-10

  Provided are methods and medicaments for treating a learning disability or a Motor Skills Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.